Literature DB >> 15763593

Estrogen receptor-alpha, bcl-2 and c-myc gene expression in fibroadenomas and adjacent normal breast: association with nodule size, hormonal and reproductive features.

R Cericatto1, A Pozzobon, D M Morsch, C H Menke, I S Brum, P M Spritzer.   

Abstract

Fibroadenomas are the most common benign lump in females. The study of gene alterations and/or deregulation in reproductive years may help explain hormonal physiological processes involved in nodule development and evolution. The objective was to compare ER-alpha, c-myc, and bcl-2 gene expression in breast fibroadenomas and in normal tissue and evaluate menstrual cycle, parity, and oral contraceptive influences. Fifty-seven premenopausal women (14-49 years) undergoing surgical removal of fibroadenomas were selected. Samples from fibroadenomas and circumjacent normal tissue were obtained for RT-PCR paired analysis. Patients were divided in groups according to menstrual cycle, use of contraceptives and parity. Tissue from 32 patients was adequate for RT-PCR. Paired analysis showed higher expression of ER-alpha (P=0.012) and bcl-2 (P=0.001) in fibroadenomas than in normal breast, while c-myc presented a similar expression (P=0.655). ER-alpha was higher in fibroadenomas of patients in follicular phase versus contraceptive users and normal tissue (P=0.003); bcl-2 was higher in fibroadenomas of patients in luteal phase than in the normal samples from all groups (P=0.007). c-myc did not differ according to menstrual cycle, but was higher in fibroadenomas>3 cm versus<3 cm (P=0.015) and in nulliparous women (P=0.04). A positive correlation between c-myc levels and fibroadenoma diameter was demonstrated (r=0.536; P=0.007). Nulliparous mean nodule diameter was superior than parous women (P=0.008). In conclusion, the expression of ER-alpha, bcl-2 and c-myc depends on hormonal and reproductive factors, with a possible contribution to lump formation and evolution.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15763593     DOI: 10.1016/j.steroids.2004.10.013

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  7 in total

1.  Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle.

Authors:  M F Rego; M A L H Navarrete; G Facina; R Falzoni; R Silva; E C Baracat; A C P Nazario
Journal:  Cell Prolif       Date:  2009-04       Impact factor: 6.831

2.  Progesterone receptors A and B and estrogen receptor alpha expression in normal breast tissue and fibroadenomas.

Authors:  Gisele Branchini; Lolita Schneider; Rodrigo Cericatto; Edison Capp; Ilma Simoni Brum
Journal:  Endocrine       Date:  2009-04-15       Impact factor: 3.633

3.  Clinical characteristics of breast cancers in African-American women with benign breast disease: a comparison to the surveillance, epidemiology, and end results program.

Authors:  Susanna D Mitro; Rouba Ali-Fehmi; Sudeshna Bandyopadhyay; Baraa Alosh; Bassam Albashiti; Derek C Radisky; Marlene H Frost; Amy C Degnim; Julie J Ruterbusch; Michele L Cote
Journal:  Breast J       Date:  2014-09-08       Impact factor: 2.431

4.  Gene and protein expression of p53 and p21 in fibroadenomas and adjacent normal mammary tissue.

Authors:  Lolita Schneider; Gisele Branchini; Rodrigo Cericatto; Edison Capp; Ilma Simoni Brum
Journal:  Endocrine       Date:  2008-11-11       Impact factor: 3.633

Review 5.  Molecular Portrait of the Normal Human Breast Tissue and Its Influence on Breast Carcinogenesis.

Authors:  Madalin Marius Margan; Andreea Adriana Jitariu; Anca Maria Cimpean; Cristian Nica; Marius Raica
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

6.  ERα activity depends on interaction and target site corecruitment with phosphorylated CREB1.

Authors:  Melissa Berto; Valerie Jean; Wilbert Zwart; Didier Picard
Journal:  Life Sci Alliance       Date:  2018-06-07

Review 7.  Expanding Roles of De Novo Lipogenesis in Breast Cancer.

Authors:  Pasquale Simeone; Stefano Tacconi; Serena Longo; Paola Lanuti; Sara Bravaccini; Francesca Pirini; Sara Ravaioli; Luciana Dini; Anna M Giudetti
Journal:  Int J Environ Res Public Health       Date:  2021-03-30       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.